Hikma Pharmaceuticals

Hikma is an international pharmaceutical company conducting operations through three businesses: generic pharmaceuticals, branded pharmaceuticals and injectable pharmaceuticals. The company sells 113 branded and non-branded generic pharmaceutical products in 34 countries worldwide. The majority of Hikma’s operations are in the United States, the Middle East and North Africa Region and Europe.

All Articles

Hikma Pharmaceuticals today said it has received approval to launch its new KLOXXADO nasal spray for the emergency treatment of

April 30, 2021

London-based Hikma Pharmaceuticals has said it expects a huge rise in annual core operating profit for the year, after being

February 25, 2021

Easyjet looks set to be the next company to fall out of the FTSE 100, with several others, including Marks

June 2, 2019

By Graeme Evans from interactive investor. The FTSE 100 outperformed mid-caps last tax year, but the top FTSE 350 performers

April 15, 2019

Today's City Moves covers pharma, investment, IT and City Moves. Take a look at these movers and shakers: Hikma Pharmaceuticals

October 5, 2018

The shake-up revealed as a result of the quarterly review of the FTSE 100 and 250 takes effect this morning.Hikma Pharmaceuticals

March 23, 2015

Tullow Oil and Afren are likely to slip out of their respective FTSE indexes after this week's quarterly review.Analysis by

March 2, 2015

Content tagged with "Hikma Pharmaceuticals"